Oncology News | pharmaphorum

News

AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.

News

Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.

News

Eli Lilly is offering AI-powered drug discovery models developed at a cost of around $1 billion to biotech companies for free.

News

Lilly's fast-growing blood cancer drug Jaypirca could gain more momentum thanks to a trial suggesting it could move into the first-line setting.

News

League tables for NHS trusts will end the postcode lottery of care, says the government, but not all are convinced.

News

Highlights of the WCLC show include new data for AstraZeneca's Tagrisso, Summit's ivonescimab, MSD/Daiichi's I-DXd, and BMS/Systimmune's iza-bren.